2018 Board Review Pre-Test:
Cardio-Oncology

Cardio-Oncology - Anju Nohria, MD, MSc

Please complete this brief Pre-Test to give a baseline for learning .

Question Title

* 1. A 65 yo woman with a h/o HTN presents with ER+/PR+ recurrent breast cancer. She was previously treated with 4 cycles of AC chemotherapy (240 mg/m2) and L breast irradiation. Her oncologist wants to give her additional anthracyclines.
Which of the following has conclusively been shown to prevent cardiotoxicity?

A. Dexrazoxane

B. Statins

C. Angiotensin converting enzyme inhibitors l

D. Carvedilo

Question Title

* 2. Which of the following statements is true about trastuzumab vs. anthracycline cardiotoxicity?

A. Both are dose-dependent toxicities

B. Pts w/ CV risk factors or pre-existing CV disease are only at increased risk for anthracycline toxicity

C. Trastuzumab cardiotoxicity is characterized by myocyte dysfunction, while anthracycline cardiotoxicity is characterized by myocyte death

D. ACEi and B-blockers are effective at preventing cardiotoxicity from both trastuzumab and anthracyclines

Question Title

* 3. A 60 y.o. man with metastatic lung cancer was treated with chemoRT consisting of carboplatin and paclitaxel. He was switched to pembrolizumab for disease progression. He presents with chest pain and lightheadedness. EKG shows new complete heart block and RBBB. Which is the most likely cause of his symptoms?

A. Radiation

B. Carboplatin

C. Pembrolizumab

D. Paclitaxel

Question Title

* 4. Please provide your first and last name.
Pre-test questions will not be scored, your name is required solely to confirm completion.

First Name *

Last Name